Antonella Sistigu
Overview
Explore the profile of Antonella Sistigu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
6348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tozzi M, Fiore A, Travaglione S, Marcon F, Rainaldi G, Germinario E, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):29.
PMID: 39876002
Background: Bacterial toxins are emerging as promising hallmarks of colorectal cancer (CRC) pathogenesis. In particular, Cytotoxic Necrotizing Factor 1 (CNF1) from E. coli deserves special consideration due to the significantly...
2.
Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, et al.
Nat Immunol
. 2024 Sep;
25(11):2166.
PMID: 39289560
No abstract available.
3.
Manduca N, Maccafeo E, De Ninno A, Sistigu A, Musella M
J Vis Exp
. 2024 Jun;
(208).
PMID: 38912773
Fundamental cancer research and the development of effective counterattack therapies both rely on experimental studies detailing the interactions between cancer and immune cells, the so-called cancer-immunity cycle. In vitro co-culture...
4.
Musella M, Manduca N, Maccafeo E, Ruggiero E, Sistigu A
Methods Mol Biol
. 2023 Dec;
2748:13-28.
PMID: 38070104
A cardinal principle of oncoimmunology is that cancer cells can be eliminated by tumor-infiltrating cytotoxic CD8 T lymphocytes. This has been widely demonstrated during the last 20 years and also...
5.
Agostini A, Guerriero I, Piro G, Quero G, Roberto L, Esposito A, et al.
J Transl Med
. 2023 Nov;
21(1):843.
PMID: 37996891
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. This is due to its aggressive course, late diagnosis and its intrinsic drugs resistance. The complexity of the tumor, in terms...
6.
Musella M, Manduca N, Maccafeo E, Sistigu A
Oncogene
. 2023 Aug;
42(39):2932-2938.
PMID: 37604925
Immunogenic- and immune-therapies have become hot spots in the treatment of cancer. Although promising, these strategies are frequently associated with innate or acquired resistance, calling for combined targeting of immune...
7.
Manduca N, Maccafeo E, De Maria R, Sistigu A, Musella M
Front Immunol
. 2023 Apr;
14:1175503.
PMID: 37114038
Cancer immunotherapy is the great breakthrough in cancer treatment as it displayed prolonged progression-free survival over conventional therapies, yet, to date, in only a minority of patients. In order to...
8.
Vitale I, Pietrocola F, Guilbaud E, Aaronson S, Abrams J, Adam D, et al.
Cell Death Differ
. 2023 Apr;
30(5):1097-1154.
PMID: 37100955
Apoptosis is a form of regulated cell death (RCD) that involves proteases of the caspase family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis in mammalian systems have...
9.
Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, et al.
Nat Immunol
. 2022 Aug;
23(9):1379-1392.
PMID: 36002648
Cancer stem cells (CSCs) are a subpopulation of cancer cells endowed with high tumorigenic, chemoresistant and metastatic potential. Nongenetic mechanisms of acquired resistance are increasingly being discovered, but molecular insights...
10.
Galassi C, Musella M, Manduca N, Maccafeo E, Sistigu A
Cells
. 2021 Sep;
10(9).
PMID: 34572009
Cancer stem cells (CSCs) are broadly considered immature, multipotent, tumorigenic cells within the tumor mass, endowed with the ability to self-renew and escape immune control. All these features contribute to...